14,515 Shares in Merck & Co., Inc. $MRK Purchased by Tulsa Wealth Advisors INC

Tulsa Wealth Advisors INC bought a new stake in Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, Holdings Channel reports. The fund bought 14,515 shares of the company’s stock, valued at approximately $1,528,000.

Other large investors have also recently bought and sold shares of the company. Integrated Investment Consultants LLC raised its position in shares of Merck & Co., Inc. by 53.9% during the 4th quarter. Integrated Investment Consultants LLC now owns 28,816 shares of the company’s stock worth $3,033,000 after buying an additional 10,087 shares in the last quarter. NWF Advisory Services Inc. lifted its stake in shares of Merck & Co., Inc. by 8.2% in the 4th quarter. NWF Advisory Services Inc. now owns 16,365 shares of the company’s stock worth $1,723,000 after acquiring an additional 1,247 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $389,000. Reflection Asset Management bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $401,000. Finally, CFO Capital Management LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $615,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on MRK shares. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. UBS Group increased their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Wells Fargo & Company lowered their price target on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Barclays assumed coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They set an “overweight” rating and a $140.00 price target on the stock. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Price Performance

NYSE MRK opened at $114.04 on Friday. The stock has a market capitalization of $281.65 billion, a P/E ratio of 32.12, a P/E/G ratio of 2.56 and a beta of 0.21. Merck & Co., Inc. has a 1 year low of $76.66 and a 1 year high of $125.14. The business’s fifty day moving average is $115.94 and its two-hundred day moving average is $113.60. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company’s revenue was up 4.9% compared to the same quarter last year. During the same period last year, the company posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts forecast that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.